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Abstract 
In the present study, we developed some novel gene delivery vectors, coated cationic 
complexes with γ-polyglutamic acid (γ-PGA) for effective and safe gene therapy.  Cationic 
complexes were constructed with pDNA and cationic vectors, such as poly-L-arginine 
hydrochloride (PLA), poly-L-lysine hydrobromide (PLL), N-[1-(2, 3-dioleyloxy) propyl]-N, 
N, N-trimethylammonium chloride (DOTMA)-cholesterol (Chol) liposomes, and 
DOTMA-dioleylphosphatidylethanolamine (DOPE) liposomes.  The cationic complexes 
showed high gene expression with strong cytotoxicity in melanoma B16-F10 cells.  The 
cationic complexes were also strongly toxic to erythrocytes.  On the other hand, the γ-PGA 
was able to coat all cationic complexes and form stable nano-sized particles with negative 
charges.  These γ-PGA-coated complexes had high gene expression without cytotoxicity and 
toxicities to the erythrocytes.  In in vivo transfection experiments, polyplexes showed high 
transfection efficiency over 105 RLU/g lung tissue after intravenous injection, although 
γ-PGA-coated polyplexes showed a high value in the spleen.  High transfection efficiency in 
lipoplexes and γ-PGA-coated lipoplexes was observed in the spleen and lung.  Thus, 
γ-PGA-coated vectors are useful for clinical gene therapy. 
 
Key words: non-viral gene delivery; cationic polymer; cationic liposome; ternary complex; 
γ-polyglutamic acid.  
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1. Introduction 
Gene therapy, which involves the intracellular delivery of DNA either to block a 
dysfunctional gene or to deliver a therapeutic gene, has huge potential for treating intractable 
diseases such as cancer and cardiovascular disorders [1,2].  Gene delivery vectors are 
categorized as viral or non-viral vectors.  In light of recent concerns about safety, non-viral 
gene delivery has emerged as a promising method, because non-viral vectors have advantages 
such as much lower immunotoxicity, a clear structure, and easy modeling [3-5]. 
Among non-viral vectors, cationic polymers and cationic liposomes have often been used 
to form stable cationic complexes with pDNA as polyplexes and lipoplexes, respectively, and 
show high gene expression in vitro and in vivo [6,7].  These cationic complexes, however, 
have been reported to show cytotoxicity and agglutination by their strong cationic surface 
charge [8,9]. 
Recharging cationic complexes with anionic compound was reported to be a promising 
method for overcoming these adverse effects [10,11].  In a previous study, we discovered an 
anionic coating, γ-polyglutamic acid (γ-PGA), which decreased the toxicities of cationic 
complexes without reductions of efficacies [12].   
In the present study, we evolved the polyplexes and lipoplexes to the safe and effective 
gene delivery vectors using γ-PGA for clinical gene therapy.  We constructed the cationic 
cores with pDNA and cationic peptide such as poly-L-arginine hydrochloride (PLA) and 
poly-L-lysine hydrobromide (PLL) or cationic liposomes such as N-[1-(2, 3-dioleyloxy) 
propyl]-N, N, N-trimethylammonium chloride (DOTMA)-cholesterol (Chol) liposomes and 
DOTMA-dioleylphosphatidylethanolamine (DOPE) liposomes; and we successfully coated 
the cationic cores with γ-PGA.  Then, γ-PGA-coated vectors showed high efficiencies with 
markedly low toxicities.   
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2. Materials and Methods 
2.1. Chemicals 
PLA (average molecular weight 22500), PLL (average molecular weight 10000), and 
bovine serum albumin (BSA) were obtained from Sigma Chemical Co. (St. Louis, MO, USA).  
DOTMA was purchased from Tokyo Chemical Industry Co. Ltd. (Tokyo, Japan).  Chol was 
obtained from Nacalai Tesque, Inc. (Kyoto, Japan).  DOPE was purchased from Nippon Oil 
and Fats Co. (Tokyo, Japan).  γ-PGA was provided by Yakult Pharmaceutical Co., Ltd. 
(Tokyo, Japan).  Fetal bovine serum (FBS) was obtained from Biosource International Inc. 
(Camarillo, CA, USA).  RPMI 1640, Opti-MEM® I, antibiotics (penicillin 100 U/mL and 
streptomycin 100 µg/mL), and other culture reagents were obtained from GIBCO BRL 
(Grand Island, NY, USA).  The 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2, 
4-disulfophenyl)-2H-tetrazolium, monosodium salt (WST-1) and 
1-methoxy-5-methylphenazinium methylsulfate (1-methoxy PMS) were obtained from 
Dojindo Laboratories (Kumamoto, Japan).  All other chemicals were of the highest purity 
available. 
 
2.2. Construction of pDNA 
pCMV-luciferase (pCMV-Luc) was constructed by subcloning the Hind III/Xba I firefly 
luciferase cDNA fragment from the pGL3-control vector (Promega, Madison, WI, USA) into 
the polylinker of the pcDNA3 vector (Invitrogen, Carlsbad, CA, USA).  Enhanced green 
fluorescence protein (GFP) encoding pDNA (pEGFP-C1) was purchased from Clontech (Palo 
Alto, CA, USA).  pDNA was amplified using an EndoFree® Plasmid Giga Kit (QIAGEN 
GmbH, Hilden, Germany), dissolved in 5% dextrose solution to 1 mg/mL, and stored at -80 
oC until analysis.  
 
2.3. Preparation of Cationic Liposomes 
DOTMA-Chol (1:1 molar ratio) and DOTMA-DOPE (1:1 molar ratio) liposomes were 
prepared according to a previous report [13].  The lipids were dissolved in chloroform and 
mixtures of each lipid were dried as a thin film in a test tube using an evaporator at 25 oC, and 
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then vacuum-desiccated for approximately 4 h.  The film was resuspended in 5% sterile 
dextrose.  After hydration, the dispersions were sonicated at 100 W (sonicator; Ohtake 
Works Co., Tokyo, Japan) for 3 min on ice.  The resulting liposomes were extruded 11 times 
through double-stacked 100 nm polycarbonate membrane filters. 
 
2.4. Preparation of Complexes 
The theoretical charge ratio of cationic polymers and liposomes to pDNA was calculated as 
the molar ratio of polymers and liposomes nitrogen to pDNA phosphate.  To prepare the 
binary complexes, appropriate amounts of stock polymer solution or liposome solution were 
mixed with a diluted solution of pDNA by pipetting thoroughly at a charge ratio of 8 for 
polyplexes or 2 for lipoplexes, and left for 15 min at room temperature.  To prepare 
γ-PGA-coated complexes, γ-PGA solution was added to binary complexes at a charge ratio of 
6, and left for another 15 min at room temperature (Fig. 1).  The theoretical charge ratio of 
γ-PGA to pDNA was calculated as the molar ratio of γ-PGA carboxylate to pDNA phosphate. 
 
2.5. Physicochemical Property and Gel Retardation Assay 
The particle size and ζ- potential of the complexes were measured with a Zetasizer Nano 
ZS (Malvern Instruments, Ltd., United Kingdom).  The number-fractioned mean diameter is 
shown. 
To determine complex formations, 10 µL aliquots of complex solution containing 1 µg 
pDNA were mixed with 2 µL loading buffer (30% glycerol and 0.2% bromophenol blue) and 
loaded onto a 0.8% agarose gel containing 0.1 µg/mL ethidium bromide.  Electrophoresis 
(Mupid®-2plus; ADVANCE, Tokyo, Japan) was carried out at 50 V in running buffer solution 
(40 mM Tris/HCl, 40 mM acetic acid, and 1 mM EDTA) for 60 min.  The retardation of the 
pDNA was visualized using a FluorChem Imaging System (Alpha Innotech, CA, USA).  
 
2.6. Transfection Experiment 
The mouse melanoma cell line, B16-F10 cells, was obtained from the Cell Resource Center 
for Biomedical Research Institute of Development, Aging and Cancer Tohoku University.  
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B16-F10 cells were maintained in culture medium (RPMI 1640 supplemented with 10% FBS 
and antibiotics) under a humidified atmosphere of 5% CO2 in air at 37 
oC.  B16-F10 cells 
were plated on 24-well collagen-containing plates (Becton-Dickinson, Franklin Lakes, NJ, 
USA) at a density of 1.5 × 104 cells/well and cultivated in 1.0 mL culture medium. 
In the transfection experiment, after 24 h pre-incubation, the medium was replaced with 1 
mL Opti-MEM® I medium and each complex containing 1 µg pCMV-Luc was added to the 
cells, and incubated for 2 h.  After transfection, the medium was replaced with culture 
medium and cells were cultured for a further 22 h at 37 oC.  After 22 h incubation, the cells 
were washed with PBS and then lysed in 100 µL lysis buffer (pH 7.8 and 0.1 M Tris/HCl 
buffer containing 0.05% Triton X-100 and 2 mM EDTA).  Ten microliters of lysate samples 
were mixed with 50 µL luciferase assay buffer (PicaGene®; Toyo Ink, Tokyo, Japan) and the 
light produced was immediately measured using a luminometer (Lumat LB 9507; EG & G 
Berthold, Bad Wildbad, Germany).  The protein content of the lysate was determined by the 
Bradford assay using BSA as a standard.  Absorbance was measured using a microplate 
reader (Multiskan Spectrum; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 570 nm.  
Luciferase activity was indicated as relative light units (RLU) per mg protein.   
To visualize gene expressions, B16-F10 cells were transfected by complexes containing 
pEGFP-C1.  After 22 h incubation, the relative levels of GFP expression were characterized 
using fluorescent microscopy (200× magnification).  
For experiments using inhibitors, the cells were transfected by the various γ-PGA-coated 
complexes in Opti-MEM® I medium containing 20 µM of L-glutamic acid or γ-PGA.  After 
transfection, medium was replaced with culture medium and cells were cultured for a further 
22 h at 37 oC, and then the luciferase activities were determined as described above. 
 
2.7. WST-1 Assay 
Cytotoxicity tests of complexes on B16-F10 cells were carried out using a WST-1 
commercially available cell proliferation reagent.  B16-F10 cells were plated on 96-well 
plates (Becton-Dickinson, Franklin Lakes, NJ, USA) at a density of 3.0 × 103 cells/well in 
culture medium.  Complexes containing 1 µg pDNA in 100 µL Opti-MEM® I medium were 
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added to each well and incubated for 2 h.  After incubation, the medium was replaced with 
100 µL culture medium and incubated for another 22 h.  Medium was then replaced with 100 
µL culture medium and 10 µL WST-1 reagent (4.95 mM WST-1 and 0.2 mM 1-methoxy 
PMS) was added to each well.  The cells were incubated for an additional 2 h at 37 oC and 
absorbance was measured at a wavelength of 450 nm with a reference wavelength of 630 nm 
using a microplate reader.  The results are shown as a percentage of untreated cells.  
 
2.8. Animals 
Animal care and experimental procedures were performed in accordance with the 
Guidelines for Animal Experimentation of Nagasaki University with approval from the 
Institutional Animal Care and Use Committee.  Male ddY mice (5–6 weeks old) were 
purchased from Japan SLC (Shizuoka, Japan).  After shipping, mice were acclimatized to the 
environment for at least one week before the experiments. 
 
2.9. Interaction with Erythrocytes 
Erythrocytes from mice were washed three times at 4 oC by centrifugation at 5000 rpm 
(Kubota 3700; Kubota, Tokyo, Japan) for 5 min and resuspended in PBS.  A 2% (v/v) stock 
suspension of erythrocytes was prepared for agglutination study.  The complexes were added 
to the erythrocyte suspension and incubated for 15 min at room temperature.  The 10 µL 
sample was placed on a glass plate and agglutination was observed by microscopy (400× 
magnifications).  For hemolysis study, 5% stock suspensions of erythrocytes were prepared.  
The complexes were added to erythrocytes and incubated for 1 h at room temperature.  After 
incubation, the suspensions were centrifuged at 5000 rpm for 5 min, and supernatants were 
taken.  Hemolysis was quantified by measuring hemoglobin release at 545 nm using a 
microplate reader.  Lysis buffer was added to erythrocytes and used for the 100% hemolysis 
sample. 
 
2.10. In Vivo Gene Expression Experiment 
Complexes, including 40 µg pCMV-Luc, were prepared for in vivo gene expression 
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experiments.  A 300 µL aliquot of complex solution was injected into mice via the tail vein.  
The liver, kidney, spleen, heart, and lung of mice were dissected 6 h after the injection.  The 
tissues were washed twice with cold saline and homogenized with lysis buffer.  
Homogenates were centrifuged at 15000 rpm for 5 min and the supernatants were used for 
luciferase assays.  Luciferase activity was indicated as RLU per gram of tissue. 
 
2.11. Statistical Analysis 
Results are expressed as the mean ± S.E. of at least three experiments.  Statistical analysis 
was performed using Student t-test.  A multiple comparison test was performed using 
Dunnett’s test with Bonferroni’s correction for multiple comparisons.  P < 0.05 was 
considered to indicate significance.  
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3. Results 
3.1. Physicochemical Property 
The particle size and ζ-potential of each complex are shown in Table 1.  Polyplexes had a 
smaller particle size than lipoplexes, but both polyplexes and lipoplexes had a cationic charge 
of 41.5–54.4 mV in ζ-potential.  The addition of γ-PGA significantly increased the particle 
size of polyplexes (P < 0.01), but did not affect the particle size of lipoplexes.  All 
γ-PGA-coated complexes showed anionic charges and had significantly lower ζ-potential than 
each binary complex (P < 0.01).  
 
3.2. Electrophoresis Assay 
Complex formations were examined by a gel retardation assay (Fig. 2).  Naked pDNA was 
detected as bands on agarose gel, but were not detected for all complexes. 
 
3.3. In Vitro Transfection Efficiency  
In vitro gene expression efficiency of various complexes was determined with B16-F10 
cells (Fig. 3).  In polyplexes, PLA/pDNA and PLL/pDNA showed 5.4 × 107 and 2.6 × 106 
RLU/mg protein, respectively.  Lipoplexes of DOTMA-Chol/pDNA and 
DOTMA-DOPE/pDNA showed a high gene expression over 108 RLU/mg protein.  Gene 
expressions of all γ-PGA-coated complexes were larger than those of each binary complex. In 
particular, γ-PGA-coated PLA/pDNA showed a significantly higher value than PLA/pDNA (P 
< 0.01).   
 
3.4. Fluorescent Microscopy 
B16-F10 cells were transfected with complexes containing pEGFP-C1 to visualize the gene 
expression (Fig. 4).  Bright green fluorescence of GFP was observed in many cells treated 
with the complexes.  γ-PGA-coated complexes showed more cells expressing GFP than each 
binary complex.   
 
3.5. Inhibition Study 
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Inhibition studies were performed with L-glutamic acid and γ-PGA (Fig. 5).  L-glutamic 
acid did not affect the transfection efficiencies of γ-PGA-coated complexes.  In contrast, 
transfection efficiencies of γ-PGA-coated complexes were significantly decreased by γ-PGA 
(P < 0.05). 
 
3.6. Cytotoxicity  
The complexes were added to B16-F10 cells and cell viability was evaluated by WST-1 
assay (Fig. 6).  Polyplexes and lipoplexes showed significantly higher cytotoxicity than the 
control (P < 0.01) and the cytotoxicity of lipoplexes was lower than that of polyplexes.  On 
the other hand, γ-PGA-coated complexes showed markedly low cytotoxicity compared with 
each binary complex.   
 
3.7. Interaction with Erythrocytes 
The complexes were incubated with erythrocytes to evaluate agglutination (Fig. 7A).  
Severe agglutination was observed in binary complexes on microscopy, whereas no 
agglutination was observed in γ-PGA-coated complexes.  Figure 7B shows the hemolysis 
activities of the complexes, with polyplexes and γ-PGA-coated polyplexes showing little 
hemolysis (less than 10%).  Strong hemolysis of erythrocytes, 79.3% and 67.8%, was 
observed in lipoplexes of DOTMA-CHOL/pDNA and DOTMA-DOPE/pDNA, respectively; 
γ-PGA coating of lipoplexes significantly suppressed hemolysis (P < 0.01).   
 
3.8. In Vivo Transfection Efficiency  
 In vivo transgene efficiency of complexes was examined in ddY male mice (Fig. 8).  
Luciferase activities in several tissues were determined 6 h after intravenous administration of 
the complexes.  Polyplexes showed high gene expression over 105 RLU/g tissue in the lung; 
however, γ-PGA-coated polyplexes showed high gene expression in the spleen.  On the other 
hand, in lipoplexes, high gene expression was observed in the spleen and lung of 
DOTMA-Chol/pDNA, and in the spleen of DOTMA-DOPE/pDNA.  γ-PGA-coated 
lipoplexes also showed high gene expression in the spleen and lung; however, γ-PGA coating 
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of DOTMA-Chol/pDNA significantly decreased the gene expression of DOTMA-Chol/pDNA 
in the lung (P < 0.05).   
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4. Discussion 
A wide range of non-viral vectors has been developed, such as cationic polymers and 
cationic lipids, for successful gene therapy [14,15].  Among cationic polymers, PLA and 
PLL are considered to have an advantage for clinical use because of their biodegradable 
peptide structure [16,17].  PLA and PLL formed stable particles as self-assembly complexes 
with pDNA, and the particle size of PLA and PLL polyplexes showed 33.9 and 50.4 nm with 
positive ζ-potential of +44.8 and +54.4 mV, respectively (Table 1).  The γ-PGA coating of 
each polyplex significantly increased the particle size.  Anionic γ-PGA may weaken the 
compaction of polymer and pDNA; however, γ-PGA did not release pDNA from the polyplex, 
as shown in Fig. 2, and the formation of stable ternary complexes was indicated.  These 
γ-PGA-coated complexes showed an apparently anionic surface charge even if their total 
charge ratio was +1.  This result suggested that the anionic coating of γ-PGA was 
concentrated on the surface of polyplexes.  
Among cationic liposomes, DOTMA-DOPE is commercially supplied as a transfection 
reagent “lipofectin”, which was demonstrated to have high transfection efficiency in cells, and 
had relatively stable expression in several tissues [18,19].  The lipoplex 
DOTMA-Chol/pDNA was reported to have higher stability and expression than lipofectin 
under in vivo conditions [20].  DOTMA-Chol and DOTMA-DOPE liposomes also 
constructed stable nano-particles with 98.7 and 115.0 nm particle sizes and +41.5 and +47.8 
mV ζ-potentials, respectively (Table 1).  γ-PGA-coating of lipoplexes did not influence 
particle size, although γ-PGA coating significantly decreased ζ-potentials of lipoplexes.  
Furthermore, γ-PGA did not release pDNA from lipoplexes, suggesting the anionic coating of 
γ-PGA on surface of lipoplexes (Fig. 2).  It is valuable to note that the addition of γ-PGA to 
polyplexes and lipoplexes can form stable anionic complexes coated by γ-PGA. 
In cationic systems, strong electrostatic interaction with a negatively charged cellular 
membrane can contribute to high gene expression through the endocytotic pathway [21].  We 
compared the transfection efficiency of each complex in mouse melanoma cell lines, B16-F10 
cells, which are often used to examine the basic gene expression of non-viral vectors [22-24].  
Polyplexes and lipoplexes showed high gene expressions although lipoplexes were more 
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effective than polyplexes (Fig. 3).  Itaka et al. reported that polyplexes with PLA and PLL 
showed high gene expression although their gene expressions were lower than the polyplex 
with PEI [25].  It was also reported that the PLL/pDNA polyplex showed lower transfection 
efficiency than PEI/pDNA polyplex because of a lack of amino groups allowing 
endosomolysis [26].  The lower gene expressions of PLA/pDNA and PLL/pDNA may be 
explained by their weak intracellular trafficking.   
Generally, anionic complexes are not taken up well by cells because they repulse the 
cellular membrane electrostatically, whereas γ-PGA-coated complexes showed higher gene 
expressions than each binary complex.  In particular, γ-PGA coating of PLA/pDNA 
increased to a 7.4-fold gene expression from PLA/pDNA (Fig. 3).  The high gene 
expressions of ternary complexes were also confirmed as the visualized GFP expressions by 
the observation of fluorescent microscopy images (Fig. 4).  The γ-PGA-coated complexes 
with an anionic charge must therefore have a different uptake mechanism from polyplexes 
and lipoplexes with a cationic charge. 
For clarifications of the uptake mechanisms, each γ-PGA-coated complex was added to the 
cells in the medium containing 20 µM of L-glutamic acid or γ-PGA (Fig. 5).  Transfection 
efficiencies of γ-PGA-coated complexes were significantly decreased by γ-PGA, not 
L-glutamic acid.  These results indicated that γ-PGA-coated complexes with anionic charges 
were taken by the cells via γ-PGA-specific receptor-mediated pathway.  The γ-PGA-coated 
DOTMA-DOPE/pDNA, however, was less inhibited by γ-PGA than other complexes.  The 
surface of γ-PGA-coated DOTMA-DOPE/pDNA might be different from other γ-PGA-coated 
complexes.   
The strong positive charges of polyplexes and lipoplexes are known to cause severe 
cytotoxicity by interaction with the negative surface of the cellular membrane [27].  In this 
experiment, polyplexes and lipoplexes also showed strong cytotoxicity (Fig. 6), although 
γ-PGA coating markedly decreased the cytotoxicity of each binary complex.  The change in 
the surface charge from positive to negative must decrease the interaction of complexes with 
the cellular surface.  It was also reported that cationic polyplexes and lipoplexes often caused 
agglutination of erythrocytes and albumin because of their strong electrostatic interaction 
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[8,9].  These agglutinations often lead to rapid elimination and adverse effects, such as 
embolism and inflammatory reaction [28-31].  The present polyplexes and lipoplexes 
severely agglutinated erythrocytes, and lipoplexes showed hemolysis activity (Figs. 7A and 
7B).  The high hemolytic activities of lipoplexes may be caused by interaction of the lipid 
component with the erythrocyte membrane.  On the other hand, γ-PGA-coated complexes 
with an anionic charge showed no agglutination activities and γ-PGA-coating significantly 
reduced hemolysis by lipoplexes (P < 0.01).  
For the clinical gene therapy, not only high transfection efficiency but also biocompatibility 
for frequent dosing is indispensable.  It was notable that γ-PGA-coating increased the 
transfection efficiency of each binary complex and markedly decreased their toxicity, 
indicating their utility as a clinical gene delivery system.   
We therefore determined the in vivo transgene efficiencies of γ-PGA-coated complexes.  
After intravenous injection of the complexes into mice, luciferase activities in five organs, the 
liver, kidney, spleen, heart, and lung, were determined by luciferase assay.  Polyplexes and 
lipoplexes showed high transfection efficiency in the lung (Fig. 8).  This high gene 
expression in the lung may be associated with agglutination, which was suggested to be 
embolized in the pulmonary vein and showed high accumulation in the lung.  γ-PGA-coated 
complexes decreased the lung gene expression, except for γ-PGA-coated 
DOTMA-DOPE/pDNA.  The low agglutination of γ-PGA-coated complexes can explain the 
decreased gene expression in the lung.  
γ-PGA-coated complexes showed high gene expression in the spleen.  Sutherland et al. 
reported that poly-γ-D-glutamic acid (γDPGA), which is a capsular component of Bacillus 
anthracis, was mainly accumulated in the spleen and liver after intravenous injection into 
mice [32,33].  In particular, γDPGA was located in red pulp in the spleen and Kupffer cells 
and sinusoidal endothelial cells in the liver.  γ-PGA-coated complexes may be taken up by 
splenic macrophage through a similar mechanism of γDPGA.  Non-coating lipoplexes also 
showed high gene expression in the spleen, although the uptake mechanism of lipoplexes 
must be different from γ-PGA-coated complexes.   
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5. Conclusion 
In this experiment, we developed some novel vectors for clinical gene therapy.  Those 
vectors showed high transfection efficiencies with extremely low toxicities.  Further study is 
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Figure legends  
 
Fig. 1. Formation of γ-PGA-coated vectors with negative ζ-potential. 
 
Fig. 2. Electrophoresis analysis. 
Each complex was loaded onto agarose gel for electrophoresis.  Retardation of pDNA was 
visualized using ethidium bromide.  
 
Fig. 3. Transfection efficiencies of various complexes. 
B16-F10 cells were transfected with the various complexes.  22 h after transfection, cells 
were lysed and luciferase activities were determined.  Each value represents the mean ± S.E. 
(n= 3-6).  **: P < 0.01. 
 
Fig. 4. Fluorescent microscopy images of B16-F10 cells transfected with various complexes. 
Cells were treated with each complex containing pEGFP-C1.  GFP expressions were 
observed 22 h after transfection by fluorescent microscopy (200× magnification).  (a): 
PLA/pDNA; (b): PLL/pDNA; (c): DOTMA-Chol/pDNA; (d): DOTMA-DOPE/pDNA; (e): 
γ-PGA-coating PLA/pDNA; (f): γ-PGA-coated PLL/pDNA; (g): γ-PGA-coated 
DOTMA-Chol/pDNA; (h): γ-PGA-coated DOTMA-DOPE/pDNA. 
 
Fig. 5. Effects of L-glutamic acid and γ-PGA on the transfection efficiencies of γ-PGA-coated 
complexes. 
B16-F10 cells were transfected with γ-PGA-coated complexes in the medium containing 20 
μM of L-glutamic acid or γ-PGA.  22 h after transfection, cells were lysed and luciferase 
activities were determined.  Each value represents the mean ± S.E. (n = 4).  **: P < 0.01, #: 
P < 0.05 vs. control, ##: P < 0.01 vs. control.  
 
Fig. 6. Cytotoxicity test of each complex on B16-F10 cells. 
Cell viabilities of B16-F10 cells treated with complexes were measured by WST-1 assay.  
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Cells were incubated with each complex for 2 h and cell viability was measured 22 h after 
transfection.  Data represent the percentage to untreated cells.  Each value represents the 
mean ± S.E. (n = 8-12).  **: P < 0.01, # #: P < 0.01 vs. control.  
 
Fig. 7. Interactions of various complexes with erythrocytes. 
The complexes were added to erythrocytes, and agglutination (A) and hemolysis activities 
(B) were assessed.  
Agglutination was observed by phase microscopy (400× magnification).  (a): PLA/pDNA; 
(b): PLL/pDNA; (c): DOTMA-Chol/pDNA; (d): DOTMA-DOPE/pDNA; (e): γ-PGA-coated 
PLA/pDNA; (f): γ-PGA-coated PLL/pDNA; (g): γ-PGA-coated DOTMA-Chol/pDNA; (h): 
γ-PGA-coated DOTMA-DOPE/pDNA.  
Hemolysis activity was determined by measuring hemoglobin release at 545 nm.  Each value 
represents the mean ± S.E. of three experiments.  **: P < 0.01, ##: P < 0.01 vs. lysis buffer.   
 
Fig. 8. Transgene efficiencies of the various complexes in mice. 
The complexes were injected intravenously into mice (40 g DNA per mouse).  At 6 h 
after administration, mice were sacrificed and each organ was dissected to quantify luciferase 
activity.  Each value represents the mean ± S.E. (n = 3-5).  *: P < 0.05. □: non-coating and 
■: γ-PGA-coating. 
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Tables 
Table 1. Particle size and ζ-potential of the various complexes 
  





PLA/pDNA      33.9 ± 9.1    +44.8 ± 0.3  
PLL/pDNA     50.4 ± 2.5    +54.4 ± 0.8  
DOTMA-Chol/pDNA      98.7 ± 2.7    +41.5 ± 0.2  
DOTMA-DOPE/pDNA    115.0 ± 6.1    +47.8 ± 0.4  
γ-PGA- 
coating 
PLA/pDNA      92.6 ± 1.4**   -12.6 ± 0.5**  
PLL/pDNA     76.1 ± 1.3**   -28.7 ± 0.8**  
DOTMA-Chol/pDNA     121.0 ± 5.6    -40.8 ± 0.2**  
DOTMA-DOPE/pDNA    115.0 ±1.5    -41.5 ± 0.6**  
 
Each value represents the mean ± S.E. (n=3).   
**: P < 0.01 vs. each binary complex 
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